The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Exciting updates from ASCO 2022 in the anti-EGFR rechallenge space for colorectal cancer
Christine Megerdichian Parseghian, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on the most exciting updates in colorectal cancer presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. Within the anti-EGFR rechallenge space, the Phase III PARADIGM trial (NCT02394795) demonstrated promising results when comparing the anti-EGFR, panitumumab, versus the anti-VEGFR, bevacizumab, in combination with mFOLFOX6, whereby a significant increase in overall-survival (OS) was observed in patients receiving anti-EGFR. Patients involved in this trial had progressed on previous treatment options and as such, the findings introduces a new treatment option for patients in the third-line setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
